Francisco Cervantes Requena

List of Publications by Year
in descending order

239 papers	28,384 citations	32410 55 h-index	6024 165 g-index
243 all docs	243 docs citations	243 times ranked	15790 citing authors

#	Article	IF	Citations
1	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	0.6	8
2	Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers, 2022, 14, 2331.	1.7	2
3	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia, 2021, 35, 623-627.	3.3	12
4	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 89-95.	1.8	25
5	Reply to: Correspondence on â€œNext-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosisâ€. Journal of Hepatology, 2021, 74, 252-254.	1.8	0
6	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia, 2021, 35, 3455-3465.	3.3	25
7	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). Blood, 2021, 138, 3643-3643.	0.6	7
8	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	2.0	53
9	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	2.0	8
10	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. Medicina ClÃnica (English Edition), 2020, 155, 152-158.	0.1	3
11	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. Biology of Blood and Marrow Transplantation, 2020, 26, 2237-2244.	2.0	14
12	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	2.5	7
13	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020, 34, 2138-2149.	3.3	55
14	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. Annals of Hematology, 2020, 99, 791-798.	0.8	17
15	CaracterÃsticas clÃnico-biolÃ³gicas de los pacientes con mielofibrosis: un anÃ¡lisis de 1.000 casos del Registro EspaÃ±ol de Mielofibrosis. Medicina ClÃnica, 2020, 155, 152-158.	0.3	3
16	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Annals of Hematology, 2019, 98, 2319-2328.	0.8	13
17	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	1.3	16
18	Conventional and molecular cytogenetic studies to characterize 2 complex variant Philadelphia translocations in patients with chronic myeloid leukemia. Oncology Letters, 2019, 17, 5705-5710.	0.8	5

#	Article	IF	Citations
19	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-NaÃ¯ve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. Blood, 2019, 134, 1663-1663.	0.6	5
20	Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome. Blood, 2019, 134, 2952-2952.	0.6	0
21	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	0.6	0
22	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	3.3	415
23	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	1.7	31
24	Prognostic risk models for transplant decision-making in myelofibrosis. Annals of Hematology, 2018, 97, 813-820.	0.8	7
25	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	2.2	211
26	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.4	13
27	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 25.	2.8	26
28	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. British Journal of Haematology, 2018, 181, 397-400.	1.2	34
29	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. British Journal of Haematology, 2018, 181, 133-137.	1.2	7
30	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer Journal, 2018, 8, 91.	2.8	38
31	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	2.8	13
32	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 156, 248-264.	2.0	14
33	Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes. Journal of Clinical Pathology, 2018, 71, 975-980.	1.0	12
34	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. Blood, 2018, 132, 47-47.	0.6	1
35	Excess Mortality in Polycythemia Vera and Essential Thrombocythemia. Blood, 2018, 132, 3042-3042.	0.6	2
36	Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2). Blood, 2018, 132, 4281-4281.	0.6	0

#	Article	IF	Citations
37	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. Blood, 2018, 132, 4299-4299.	0.6	0
38	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	0.6	0
39	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. Journal of Cancer Research and Clinical Oncology, 2017, 143, 843-850.	1.2	34
40	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	1.8	50
41	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2017, 178, 764-771.	1.2	22
42	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	1.7	46
43	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. European Journal of Haematology, 2017, 99, 36-41.	1.1	3
44	Predictive factors for anemia response to erythropoiesisâ€stimulating agents in myelofibrosis. European Journal of Haematology, 2017, 98, 407-414.	1.1	23
45	Does ruxolitinib prolong the survival of patients with myelofibrosis?. Blood, 2017, 129, 832-837.	0.6	81
46	Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Critical Reviews in Oncology/Hematology, 2017, 120, 52-59.	2.0	38
47	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.4	18
48	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Annals of Hematology, 2017, 96, 81-85.	0.8	28
49	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	6.9	210
50	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitorâ€"NaÃ¯ve Patients With Myelofibrosis. Journal of Clinical Oncology, 2017, 35, 3844-3850.	0.8	243
51	Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).. Journal of Clinical Oncology, 2017, 35, 7000-7000.	0.8	4
52	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. Journal of Clinical Oncology, 2017, 35, 7001-7001.	0.8	14
53	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer, 2016, 122, 1888-1896.	2.0	16
54	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	1.7	118

#	Article	IF	Citations
55	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	0.8	56
56	Alleviating anemia and thrombocytopenia in myelofibrosis patients. Expert Review of Hematology, 2016, 9, 489-496.	1.0	13
57	Long-term results of prednisone treatment for the anemia of myelofibrosis. Leukemia and Lymphoma, 2016, 57, 120-124.	0.6	16
58	A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). Blood, 2016, 128, 3110-3110.	0.6	7
59	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 3117-3117.	0.6	4
60	Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials. Blood, 2016, 128, 3118-3118.	0.6	1
61	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.. Journal of Clinical Oncology, 2016, 34, 7067-7067.	0.8	1
62	The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.. Journal of Clinical Oncology, 2016, 34, TPS7079-TPS7079.	0.8	0
63	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 5463-5463.	0.6	0
64	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood, 2015, 125, 3347-3350.	0.6	152
65	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	1.7	203
66	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Annals of Hematology, 2015, 94, 1791-1796.	0.8	57
67	Novel therapies for myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2768-2778.	0.6	7
68	BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. Leukemia Research, 2015, 39, 1278-1284.	0.4	7
69	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	3.4	362
70	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. Journal of Hepatology, 2015, 62, 72-74.	1.8	72
71	A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia. Blood, 2015, 126, 1602-1602.	0.6	2
72	Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). Blood, 2015, 126, 4029-4029.	0.6	3

#	Article	IF	Citations
73	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2015, 126, 4073-4073.	0.6	2
74	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. Blood, 2015, 126, 4080-4080.	0.6	3
75	Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial. Blood, 2015, 126, 58-58.	0.6	2
76	Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results. Blood, 2015, 126, 59-59.	0.6	7
77	The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia. Blood, 2015, 126, 595-595.	0.6	3
78	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2015, 126, 825-825.	0.6	24
79	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. Blood, 2015, 126, 5175-5175.	0.6	0
80	Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT). Blood, 2015, 126, 1609-1609.	0.6	6
81	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
82	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. Journal of Medical Economics, 2014, 17, 435-441.	1.0	8
83	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€month followâ€up. American Journal of Hematology, 2014, 89, 732-742.	2.0	102
84	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Annals of Hematology, 2014, 93, 797-802.	0.8	10
85	Use of the Functional Assessment of Cancer Therapyâ^'Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Clinical Therapeutics, 2014, 36, 560-566.	1.1	24
86	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	1.7	38
87	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	0.6	79
88	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood, 2014, 124, 729-736.	0.6	84
89	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014, 123, 1833-1835.	0.6	95
90	How I treat myelofibrosis. Blood, 2014, 124, 2635-2642.	0.6	132

#	Article	IF	Citations
91	Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia. Blood, 2014, 124, 153-153.	0.6	6
92	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. Blood, 2014, 124, 1824-1824.	0.6	9
93	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. Blood, 2014, 124, 1848-1848.	0.6	2
94	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). Blood, 2014, 124, 1849-1849.	0.6	4
95	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	0.6	1
96	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	0.6	47
97	Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. Blood, 2014, 124, 712-712.	0.6	8
98	Effect of continued imatinib (IM) in pts with detectable BCR-ABL after â‰¥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. Journal of Clinical Oncology, 2014, 32, 7025-7025.	0.8	1
99	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. Blood, 2014, 124, 633-633.	0.6	0
100	Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression. Blood, 2014, 124, 3187-3187.	0.6	0
101	Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2013, 14, 873-884.	0.9	12
102	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	0.6	286
103	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	0.6	383
104	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
105	The <scp>ERCC2 G</scp>ln/<scp>G</scp>ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	1.2	4
106	Healthâ€related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 2013, 162, 229-239.	1.2	75
107	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
108	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. Blood, 2013, 122, 1582-1582.	0.6	1

#	Article	IF	Citations
109	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. Blood, 2013, 122, 2735-2735.	0.6	1
110	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. Blood, 2013, 122, 394-394.	0.6	29
111	Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts. Blood, 2013, 122, 4066-4066.	0.6	1
112	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	0.6	6
113	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. Blood, 2013, 122, 4068-4068.	0.6	10
114	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). Blood, 2013, 122, 4070-4070.	0.6	15
115	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4087-4087.	0.6	9
116	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4088-4088.	0.6	6
117	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577.	0.6	0
118	Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only. Blood, 2013, 122, 382-382.	0.6	0
119	Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. Blood, 2013, 122, 94-95.	0.6	2
120	Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology, 2012, 30, 2981-2987.	0.8	105
121	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	13.9	1,543
122	Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets, 2012, 23, 336-343.	1.1	12
123	Prognostication in Primary Myelofibrosis. Current Hematologic Malignancy Reports, 2012, 7, 43-49.	1.2	19
124	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	0.6	2
125	Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After â‰¥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results. Blood, 2012, 120, 694-694.	0.6	3
126	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). Blood, 2012, 120, 801-801.	0.6	33

#	Article	IF	Citations
127	Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). Blood, 2012, 120, 802-802.	0.6	12
128	Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.. Journal of Clinical Oncology, 2012, 30, 6505-6505.	0.8	3
129	Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT).. Journal of Clinical Oncology, 2012, 30, 6514-6514.	0.8	5
130	Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT).. Journal of Clinical Oncology, 2012, 30, 6625-6625.	0.8	6
131	Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study.. Journal of Clinical Oncology, 2012, 30, 6626-6626.	0.8	5
132	JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly.. Journal of Clinical Oncology, 2012, 30, TPS6639-TPS6639.	0.8	1
133	Patientâ€™s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms. , 2012, , 47-55.		0
134	Cytoreduction Plus Low-Dose Aspirin Versus Cytoreduction in Monotherapy As Primary Prophylaxis of Thrombosis in Patients with Essential Thrombocythemia.. Blood, 2012, 120, 2828-2828.	0.6	0
135	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. Blood, 2012, 120, 1726-1726.	0.6	4
136	Comparison of the Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	0.6	0
137	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. Blood, 2012, 120, 1729-1729.	0.6	1
138	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 2011, 29, 392-397.	0.8	854
139	Advances in the understanding and management of primary myelofibrosis. Current Opinion in Oncology, 2011, 23, 665-671.	1.1	14
140	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
141	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
142	Practical management of patients with chronic myeloid leukemia. Cancer, 2011, 117, 4343-4354.	2.0	20
143	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leukemia Research, 2011, 35, 1014-1019.	0.4	52
144	Management of Essential Thrombocythemia. Hematology American Society of Hematology Education Program, 2011, 2011, 215-221.	0.9	43

#	Article	IF	Citations
145	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. Blood, 2011, 118, 3839-3839.	0.6	4
146	Prognostic Factors in Classic Myeloproliferative Neoplasms. , 2011, , 85-96.		0
147	Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry. Blood, 2011, 118, 1688-1688.	0.6	0
148	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. Blood, 2011, 118, 3833-3833.	0.6	0
149	Transfusionâ€dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosisâ€"prognostic relevance is independent of IPSS or karyotype. American Journal of Hematology, 2010, 85, 14-17.	2.0	46
150	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica, 2010, 95, 1317-1324.	1.7	53
151	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. Blood, 2010, 115, 745-746.	0.6	0
152	Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Annals of Hematology, 2010, 89, 1233-1237.	0.8	134
153	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 2010, 42, 722-726.	9.4	1,034
154	Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2010, 16, 358-367.	2.0	245
155	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 2010, 116, 2857-2858.	0.6	153
156	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	0.6	805
157	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	0.6	216
158	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. Blood, 2010, 116, 625-625.	0.6	64
159	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. Blood, 2010, 116, 4104-4104.	0.6	1
160	Blood cell activation in myeloproliferative neoplasms. Haematologica, 2009, 94, 1484-1488.	1.7	33
161	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	0.8	213
162	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. American Journal of Hematology, 2009, 84, 102-108.	2.0	116

#	Article	IF	Citations
163	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	0.8	1,188
164	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113, 2895-2901.	0.6	1,110
165	Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.. Blood, 2009, 114, 1904-1904.	0.6	12
166	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. Blood, 2009, 114, 2915-2915.	0.6	1
167	Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.. Blood, 2009, 114, 1909-1909.	0.6	0
168	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. Blood, 2009, 114, 3891-3891.	0.6	0
169	Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment.. Blood, 2009, 114, 3906-3906.	0.6	0
170	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. Blood, 2009, 114, 1113-1113.	0.6	0
171	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Annals of Hematology, 2008, 87, 269-276.	0.8	50
172	Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation. Clinical Leukemia, 2008, 2, 39-45.	0.2	0
173	A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2008, 112, 657-657.	0.6	4
174	Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study. Blood, 2008, 112, 663-663.	0.6	4
175	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 2007, 109, 2303-2309.	0.6	563
176	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomeâ€“positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 2007, 110, 3540-3546.	0.6	688
177	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
178	New and Old Treatment Modalities in Primary Myelofibrosis. Cancer Journal (Sudbury, Mass), 2007, 13, 377-383.	1.0	53
179	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 2007, 31, 737-740.	0.4	288
180	Myelofibrosis: biology and treatment options. European Journal of Haematology, 2007, 79, 13-17.	1.1	7

#	Article	IF	Citations
181	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. Blood, 2007, 110, 2532-2532.	0.6	0
182	Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. Best Practice and Research in Clinical Haematology, 2006, 19, 495-517.	0.7	31
183	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	0.6	1,184
184	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108, 1497-1503.	0.6	317
185	Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2006, 134, 184-186.	1.2	67
186	Non-hodgkin's lymphoma of unfavourable histology: A multivariate analysis of factors predicting the response to chop. Hematological Oncology, 2006, 5, 203-211.	0.8	5
187	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine, 2006, 355, 2408-2417.	13.9	3,212
188	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. Blood, 2006, 108, 377-377.	0.6	8
189	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. Blood, 2006, 108, 2707-2707.	0.6	0
190	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. Blood, 2006, 108, 3598-3598.	0.6	0
191	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica, 2006, 91, 169-75.	1.7	199
192	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 2005, 106, 2849-2853.	0.6	75
193	Modern management of myelofibrosis. British Journal of Haematology, 2005, 128, 583-592.	1.2	42
194	Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. British Journal of Haematology, 2005, 129, 771-775.	1.2	122
195	Myelofibrosis With Myeloid Metaplasia: Diagnosis, Prognostic Factors, and Staging. Seminars in Oncology, 2005, 32, 395-402.	0.8	23
196	Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients. Leukemia and Lymphoma, 2005, 46, 717-722.	0.6	26
197	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology, 2004, 127, 399-403.	1.2	125
198	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. British Journal of Haematology, 2004, 124, 329-335.	1.2	22

#	Article	IF	Citations
199	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis. Experimental Hematology, 2003, 31, 204-210.	0.2	39
200	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. British Journal of Haematology, 2003, 120, 500-504.	1.2	9
201	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 348, 994-1004.	13.9	3,227
202	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica, 2003, 88, 1117-22.	1.7	26
203	Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. British Journal of Haematology, 2002, 118, 786-790.	1.2	135
204	Hypercalcemia as the Presenting Feature of T-Cell Lymphoid Blast Crisis of Ph-Positive Chronic Myeloid Leukemia. Leukemia and Lymphoma, 2001, 41, 203-206.	0.6	9
205	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. European Journal of Haematology, 2001, 66, 324-327.	1.1	26
206	Deoxycoformycin in the treatment of patients with hairy cell leukemia. , 2000, 88, 352-357.		53
207	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
208	Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. European Journal of Haematology, 2000, 65, 104-108.	1.1	30
209	Blast Crisis of Ph-Positive Chronic Myeloid Leukemia with Isochromosome 17q: Report of 12 Cases and Review of the Literature. Leukemia and Lymphoma, 2000, 38, 83-90.	0.6	21
210	Non-Hodgkin's Lymphoma Following Untreated Essential Thrombocythemia. Leukemia and Lymphoma, 2000, 36, 421-423.	0.6	7
211	â€˜Lymphoidâ€™ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. British Journal of Haematology, 1998, 100, 129-134.	1.2	79
212	Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 1998, 102, 684-690.	1.2	168
213	Non-Hodgkin's Lymphoma Associated with Gaucher's Disease. Leukemia and Lymphoma, 1998, 31, 609-612.	0.6	21
214	The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. European Journal of Haematology, 1998, 60, 101-105.	1.1	36
215	Risk of relapse and clinicoâ€pathological features in 103 patients with diffuse largeâ€cell lymphoma in complete response after firstâ€line treatment. European Journal of Haematology, 1998, 61, 59-64.	1.1	11
216	Identification of â€˜shortâ€livedâ€™ and â€˜longâ€livedâ€™ patients at presentation of idiopathic myelofibrosis. British Journal of Haematology, 1997, 97, 635-640.	1.2	164

#	Article	IF	Citations
217	Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. British Journal of Haematology, 1997, 96, 421-423.	1.2	8
218	Hypercalcemia in a Patient with Chronic Lymphocytic Leukemia Evolving into Richter's Syndrome. Leukemia and Lymphoma, 1996, 21, 521-523.	0.6	12
219	An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. European Journal of Haematology, 1996, 57, 286-291.	1.1	24
220	Multiple Myeloma Following Essential Thrombocythemia. Leukemia and Lymphoma, 1995, 20, 177-179.	0.6	9
221	Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. British Journal of Haematology, 1994, 87, 293-300.	1.2	25
222	Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 1994, 88, 117-121.	1.2	56
223	Prognosis of Chronic Myeloid Leukemia: Studies from the Barcelona Group. Leukemia and Lymphoma, 1993, 11, 63-66.	0.6	35
224	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. British Journal of Haematology, 1992, 81, 178-183.	1.2	33
225	Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 1992, 81, 391-394.	1.2	140
226	Liver Dysfunction following Splenectomy in Idiopathic Myelofibrosis: A Study of 10 Patients. Acta Haematologica, 1991, 85, 184-188.	0.7	50
227	Assessment of Iron Stores in Hospitalized Patients. American Journal of Clinical Pathology, 1991, 95, 105-106.	0.4	0
228	A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. British Journal of Haematology, 1990, 76, 27-32.	1.2	49
229	Scleroderma Associated with Idiopathic Myelofibrosis. Leukemia and Lymphoma, 1990, 1, 153-155.	0.6	4
230	Bone marrow histopathology in primary myelofibrosis: Clinical and haematologic correlations and prognostic evaluation. European Journal of Haematology, 1990, 44, 95-99.	1.1	25
231	A new prognostic system for multiple myeloma based on easily available parameters. British Journal of Haematology, 1989, 72, 507-511.	1.2	39
232	Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors. European Journal of Haematology, 1989, 42, 284-288.	1.1	9
233	Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view?. European Journal of Haematology, 1989, 42, 150-154.	1.1	16
234	Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. British Journal of Haematology, 1988, 70, 279-282.	1.2	25

#	Article	IF	Citations
235	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. British Journal of Haematology, 1987, 65, 307-311.	1.2	0
236	Early Tâ€cell features in blast crisis of Ph¹â€positive chronic myeloid leukaemia. Scandinavian Journal of Haematology, 1985, 35, 71-76.	0.0	8
237	Iron stores in chronic granulocytic leukaemia at presentation. Scandinavian Journal of Haematology, 1984, 32, 469-474.	0.0	10
238	Systemic Lupus Erythematosus and Amyloidosis. Arthritis and Rheumatism, 1979, 22, 554-556.	6.7	31
239	Accurately assessing risk in your myeloproliferative neoplasm patient. , 0, , 37-44.		0